Trial Profile
A Pilot Study of Full Dose Gemcitabine and Hypofractionated Stereotactic Radiosurgery in the Treatment of Unresectable Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Apr 2012
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 23 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 23 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2011 Planned end date changed from Dec 2010 to Dec 2011 as reported by ClinicalTrials.gov.